학술논문

Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR plus ) nonsmall cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2022, 33 7, pS1067-pS1068, 2p. Supplement: 7
Subject
Language
English
ISSN
15698041